Although autologous cell transplantation circumvents the need for immunosuppressive treatment, it is not always available or most effective.
Not exact matches
Although many immunosuppressive strategies have failed, the recent use of
autologous hematopoietic stem and progenitor
cell (HSPC) transplantation has shown therapeutic promise.
Additionally, genetic modification or pre-conditioning of
autologous cells to boost the levels of VEGF [4], ANG [5], and TGF -[6], all previously linked to alleviation of ALS symptoms, could potentially lead to an augmented response,
although this must first be assessed in animal models, such as the SOD1 mice.
Autologous bone marrow mesenchymal stromal
cells (BM - MSCs) secrete factors known to improve neurological function, and clinical trials have shown BM - MSC transplantation to be safe and feasible [2],
although results have been variable.
Although regulatory precedents have been set for various
autologous and allogeneic products in the United States, Asia, and the European Union, regulatory guidance continues to evolve for a widening array of
cell products.